

# Essential Immunology

IVAN M. ROITT

THIRD EDITION

# Essential Immunology

IVAN M. ROITT

MA, DSc(Oxon), FRCPath

*Professor and Head of Department of Immunology,  
Middlesex Hospital Medical School, London W1*

THIRD EDITION

BLACKWELL SCIENTIFIC PUBLICATIONS

OXFORD LONDON EDINBURGH MELBOURNE

# Acknowledgements

## **First edition**

While not wishing to saddle my colleagues with responsibility for some of the wilder views expressed in this book it would be ungrateful of me not to acknowledge with pleasure the helpful discussions I have had with Jonathan Brostoff, George Dick, Deborah Doniach, Frank Hay, Leslie Hudson, Gerald Jones and John Playfair. I would like to express my appreciation to my secretary, Gladys Stead, who helped to prepare and assemble the manuscript with her usual impeccable expertise and who always encouraged me when my authorship seemed to be faltering. I also wish to acknowledge my debt to Valerie Petts for her excellent help with the photographs. My thanks also to the many people who supplied material for the illustrations; they are acknowledged at the appropriate place in the text. In particular, Bill Weigle kindly let me have unpublished information. Finally let me say that the pain of converting blank paper to written manuscript at home was made bearable by the loving support and understanding of my wife and family.

## **Second edition**

The necessity for a second edition has been dictated by the breakneck increase in immunological knowledge since this book was first written—clearly the subject has too many adherents! My colleagues will know how much I have appreciated their invaluable discussions; particularly I must mention Ita Askonas, Jonathan Brostoff, Deborah Doniach, Arnold Greenberg, Hilliard Festenstein, Frank Hay, M. Hobart, Leslie Hudson, D. L. Brown, John Playfair and Mac Turner. Once again I would have been lost without the admirable help of my secretary, Gladys Stead. Even the publishers have been nice!

## **Third edition**

The indecent speed at which we lurch forward has necessitated radical revision of many sections in this new edition. The

anatomical basis of the immune response, immunity to infection and the biological significance of the major histocompatibility complex have all been given fuller treatment. A summary has been added to the end of each chapter which should be a help to those poor souls for whom circumstances make revision essential. The index has received serious attention and I hope it will be of greater value. I am most grateful to the many colleagues whose wisdom I have sought: Franco Bottazzo, Jonathan Brostoff, Peter Campbell, Debroah Doniach, Hilliard Festenstein, Peter Gould, Frank Hay, Peter Lachman, Ian McConnell, John Playfair and Martin Raff. Finally, my thanks are due to Miss Christine Meats for her most able and cheerful secretarial assistance.

# Contents

	<b>Acknowledgements</b>	<b>xi</b>
<b>1</b>	<b>Introduction</b>	<b>i</b>
	Some historical perspectives	3
	The classical precipitin reaction	4
	The basis of specificity	7
	The forces binding antigen to antibody, 9; Antibody affinity, 12; Avidity and the bonus effect of multivalent binding, 15; Specificity and cross-reactions, 16; The antibody site and antigen determinants, 17	
	Further reading	19
<b>2</b>	<b>The immunoglobulins</b>	<b>21</b>
	The basic structure of the immunoglobulins	21
	Variations in structure of the immunoglobulins	25
	Structural variation in relation to antibody specificity, 29;	
	Variability in structure unrelated to antibody specificity, 31	
	Comparison of immunoglobulin classes	35
	Immunoglobulin subclasses, 40; Other immunoglobulin variants, 41	
	Further reading	44
<b>3</b>	<b>The synthesis of antibody</b>	<b>47</b>
	Two types of immune response	47
	Role of the small lymphocyte	47
	Primary response, 47; Secondary response—memory, 48	
	The thymus	51
	The Bursa of Fabricius	52
	Two populations of lymphocytes: T- and B-cells	53
	Identification of B- and T-lymphocytes, 54; Lymphocyte surface phenomena, 61	
	Cellular co-operation in the immune response	63
	The role of macrophages, 63; Co-operation between T- and B-cells, 64; Relevance to antigenicity, 66	
	The anatomical basis of the immune response	70
	Lymph node, 70; Spleen, 75; Encapsulated lymphoid tissue, 76	
	Synthesis of humoral antibody	76
	Detection of antibody-forming and antigen-sensitive cells, 76; Protein synthesis, 79; Abnormal immunoglobulin synthesis, 80; Immunoglobulin classes, 82	

	Genetical control of the immune response	83
	Genes affecting general responsiveness, 83; Immune response linked to immunoglobulin genes, 84; Immune response linked to the major histocompatibility complex, 84	
	Regulation of the immune response	86
	Immunological tolerance	88
	At birth, 88; In adult, 89; Termination of tolerance, 93	
	Ontogeny of the immune response	94
	Phylogeny of the immune response	97
	Further reading	100
<b>4</b>	<b>Theories of antibody synthesis</b>	<b>101</b>
	Instructive theory	101
	Selective theory	101
	Evidence for a selective theory	102
	Absence of antigen from plasma cells, 102; Unfolding experiments, 103; Amino acid sequence of antibodies, 103; Genetic studies, 103	
	Clonal selection model	103
	Evidence for clonal selection model	105
	One cell/one immunoglobulin, 105; Relation of surface antibody to future performance, 105	
	Validity of the clonal selection model	107
	Genetic theories of antibody variability	111
	Further reading	116
<b>5</b>	<b>Interaction of antigen and antibody <i>in vitro</i></b>	<b>119</b>
	Precipitation	119
	Quantitative precipitin curves, 119; Precipitation in gels, 119; Single radial immunodiffusion (SRID), 122; Immunoelectrophoresis, 122	
	Radioactive binding techniques	126
	Determination of antigen-binding capacity, 126; Determination of antibody binding capacity, 127; Radioimmunoassay, 128	
	Immunofluorescence	128
	Other labelled antibody methods, 132	
	Reactions with cell surface antigens	133
	Binding of antibody, 133; Agglutination, 133; Opsonic adherence, 136; Stimulation, 136; Cytotoxic reactions, 137	
	Complement	137
	Nature of complement, 137; The complement fixation test (CFT), 139; Activation of complement, 139; The complement sequence, 141; Role in defence, 144; Role in disease, 146; Complement deficiencies, 146; Genetics, 147	
	Neutralization of biological activity	147
	Further reading	149



## 6

### Hypersensitivity

151

Type I—anaphylactic sensitivity, 151; Type II—antibody-dependent cytotoxic hypersensitivity, 151; Type III—complex-mediated hypersensitivity, 151; Type IV—cell-mediated (delayed-type) hypersensitivity, 152; Type V—stimulatory hypersensitivity, 154

#### Type I—Anaphylactic sensitivity

154

Systemic anaphylaxis, 154; Mechanism of anaphylaxis, 155; Atopic allergy, 158

#### Type II—Antibody-dependent cytotoxic

hypersensitivity

160

Isoimmune reactions, 162; Autoimmune reactions, 164; Drug reactions, 166

#### Type III—Complex-mediated hypersensitivity

166

Antibody excess (Arthus-type reactivity), 167; Antigen excess (serum sickness), 170; Detection of immune complex formation, 172

#### Type IV—Cell-mediated (delayed-type)

hypersensitivity

173

Cellular basis, 174; Effector mechanisms, 176; *In vitro* tests for cell-mediated hypersensitivity, 178; Relation to antibody synthesis, 180; Tissue damage, 182

#### Type V—Stimulatory hypersensitivity

183

#### Summary of different types of hypersensitivity

185

#### Further reading

187

## 7

### Immunity to infection

189

#### Innate immunity

189

Preventing entry, 189; Counterattack against the invaders, 190;

The role of complement, 193

#### Acquired immunity

194

#### Immunity to bacterial infection

195

Role of humoral antibody, 195; role of cell-mediated immunity (CMI), 198

#### Immunity to viral infection

201

Protection by serum antibody, 202; Local factors, 202; Cell-mediated immunity, 203

#### Immunity to parasitic infections

206

Protozoa, 206; Helminths, 208

#### Prophylaxis

209

Passively acquired immunity, 209; Active immunization, 210

#### Primary immunodeficiency

216

#### Secondary immunodeficiency

220

#### Further reading

223

<b>8</b>	<b>Transplantation</b>	<b>225</b>
	Evidence that rejection is immunological	225
	Transplantation antigens	227
	Genetics, 227; The major histocompatibility complex in mice, 228; The major histocompatibility complex in man, 233	
	Rejection mechanisms	234
	Lymphocyte-mediated rejection, 234; The role of humoral antibody, 235	
	Prevention of graft rejection	239
	Tissue matching, 239; General immunosuppression, 240; Antigen-specific depression of homograft reactivity, 244	
	Clinical experience in grafting	246
	Biological significance of the major histocompatibility complex	248
	Polymorphism, 248; Immunological relationship of mother and fetus, 249; Recognition systems, 250; The cancer cell and the allograft reaction, 252; Relation of MHC to the complement system, 259; Association with disease, 259	
	Further reading	263
<b>9</b>	<b>Autoimmunity</b>	<b>265</b>
	The spectrum of autoimmune diseases	265
	Autoantibodies in human disease	266
	Overlap of autoimmune disorders	272
	Genetic factors in autoimmune disease	274
	Aetiology of autoimmune response	276
	Pathogenic mechanisms in autoimmune disease	281
	Effects of humoral antibody, 282; Effects of complexes, 287; Cellular hypersensitivity, 291; Experimental models of autoimmune disease, 294	
	Diagnostic value of autoantibody tests	297
	Treatment of autoimmune disorders	297
	Summary: comparison of organ-specific and non-organ-specific diseases	299
	Further reading	300
	<b>Appendix</b>	
	Ministry of Health schedule of vaccination and immunization procedures	303
	<b>Index</b>	<b>307</b>



# 1 Introduction

Memory, specificity and the recognition of 'non-self'—these lie at the heart of immunology. Our experience of the subsequent protection (*immunity*) afforded by exposure to many infectious illnesses can in fact lead us to this view.

We rarely suffer twice from such diseases as measles, mumps, chicken-pox, whooping cough and so forth. The first contact with an infectious organism clearly imprints some information, imparts some *memory*, so that the body is effectively prepared to repel any later invasion by that organism. This protection is provided by antibodies evoked as a response to the infectious agent behaving as an antigen (figure 1.1). Combination with antibody leads to elimination of the antigen.

By following the production of antibody on the first and second contacts with antigen we can see the basis for the development of immunity. For example, when we inject a bacterial product such as staphylococcal toxoid into a rabbit, several days elapse before antibodies can be detected in the blood; these reach a peak and then fall (figure 1.2). If we now allow the animal to rest and then give a second injection of toxoid, the course of events is dramatically altered. Within two to three days the antibody level in the blood rises steeply to reach much higher values than were observed in the *primary response*. This *secondary response* then is characterized by a more rapid and more abundant production of antibody resulting from the 'tuning up' or priming of the antibody-forming system to provide a population of memory cells after first exposure to antigen.

Vaccination utilizes this principle by employing a relatively harmless form of the antigen (e.g. a killed virus) as the primary stimulus to imprint 'memory'. The body's defences are thereby alerted and any subsequent contact with the virulent form of the organism will lead to a secondary response with an early and explosive production of antibody which will usually prevent the infection from taking hold.

*Specificity* was mentioned earlier as a fundamental feature of the immunological response. The establishment of memory or




FIGURE 1.1. Antibodies (*anti-foreign bodies*) are produced by host white cells on contact with the invading micro-organism which is acting as an antigen (i.e. *generates antibodies*). The individual may then be immune to further attacks.

immunity by one organism does not confer protection against another unrelated organism. After an attack of measles we are immune to further infection but are susceptible to other agents such as the polio or mumps viruses. The body can, in fact, differentiate specifically between the two organisms.

This ability to recognize one antigen and distinguish it from another goes even further. The individual must also recognize what is foreign, i.e. what is '*non-self*'. The failure to discriminate between '*self*' and '*non-self*' could lead to the synthesis of antibodies directed against components of the subject's own body (*autoantibodies*) which in principle could prove to be highly embarrassing. On purely theoretical grounds it seemed to Burnet and Fenner that the body must develop some mechanism whereby '*self*' and '*non-self*' could be distin-




FIGURE 1.2. *Primary and secondary response.* A rabbit is injected on two separate occasions with staphylococcal toxoid. The antibody response on the second contact with antigen is more rapid and more intense.

guished, and they postulated that those circulating body components which were able to reach the developing lymphoid system in the perinatal period could in some way be 'learnt' as 'self'. A permanent unresponsiveness or tolerance would then be created so that as immunological maturity were reached there would be an inability to respond to 'self' components. As we shall see later, these predictions have been amply verified.

It is worth emphasizing that the lower animal forms possess so-called 'non-specific immunity' mechanisms such as phagocytosis of bacteria by specialized cells, which afford them protection from infecting organisms. The *adaptive* immune response in higher animals which we have been discussing, has evolved to provide more effective defence in that appropriate immunological cells concentrate their energies on the particular agents infecting the body at any one time and the specific antibodies which they synthesize greatly speed up the disposal of these organisms by facilitating their adherence to phagocytic cells (see chapter 7). In other words the specific adaptive immune response operates to a considerable extent by increasing the efficiency of the non-specific immunity systems.

### Some historical perspectives

Space does not allow more than a cursory survey of some of the outstanding contributions to the development of immunology.

India and China (ancient times)—Practice of 'variolaion' in

which protection against smallpox was obtained by inoculating live organisms from disease pustules (dangerous!).

Jenner (1798)—Protective effect of vaccination with non-virulent cowpox against smallpox infection (noting the pretty pox-free skin of the milkmaids).

Pasteur (1881)—Vaccine for anthrax using attenuated organisms.

Metchnikoff (1883)—Role of phagocytes in immunity.

Von Behring (1890)—Recognized antibodies in serum to diphtheria toxin.

Denys & Leclef (1895)—Phagocytosis greatly enhanced by immunization.

Bordet (1899)—Lysis of cells by antibody requires co-operation of serum factors now collectively termed complement.

Landsteiner (1900)—Human ABO groups and natural isohaemagglutinins.

Richet & Portier (1902)—Anaphylaxis (opposite of prophylaxis).

Wright (1903)—Relation of opsonic activity to phagocytosis.

Zinsser (1925)—Contrast between immediate and delayed-type hypersensitivity.

Heidelberger & Kendall (1930–35)—Quantitative precipitin studies on antigen-antibody interactions.

Later work is referred to in subsequent chapters but note in particular the finding that immunization leads to more effective phagocytosis. At this stage we can examine the work of Heidelberger and Kendall and its implications in more detail and with some benefit.

### **The classical precipitin reaction**

When an antigen solution is mixed in correct proportions with a potent antiserum, a precipitate is formed. Quantitative analysis of this interaction by the method shown in figure 1.3 gives both the antibody content of the immune serum and also an indication of the valency of the antigen. This can vary enormously depending on the antigen, its size, and the species making the antibody. With rabbit antisera, ovalbumin may have a valency of 10 and human thyroglobulin as many as 40 combining sites on its surface. By splitting antigens into large fragments with proteolytic enzymes it has become clear that the separate combining areas on the surface of a given protein (called antigenic *determinants* or *epitopes*) are by no means identical.

It will be noted from the precipitin curve in figure 1.3 that as




FIGURE 1.3. Quantitative precipitin reaction between rabbit anti-ovalbumin and ovalbumin (after Heidelberger & Kendall). Increasing amounts of ovalbumin are added to a constant volume of the antiserum placed in a number of tubes. After incubation the precipitates formed are spun down and weighed. Each supernatant is split into two halves: by adding antigen to one and antibody to the other, the presence of reactive antibody or antigen respectively can be demonstrated. The antibody content of the serum can be calculated from the equivalence point where no antigen or antibody is present in the supernatant. All the antigen added is therefore complexed in the precipitate with all the antibody available and the antibody content in 0.1 ml of serum would therefore be given by  $(W_{AbAg} - W_{Ag})$ . Analysis of the precipitate formed in rabbit excess (AbXS), where the antigen-combining sites are largely saturated, gives a measure of the molar ratio of antibody to antigen in the complex and hence an estimate of the antigen valency.




FIGURE 1.4. Diagrammatic representation of complexes formed between a hypothetical tetravalent antigen (●-●-●-●) and bivalent antibody (Y-C)

mixed in different proportions. In practice, the antigen valencies are unlikely to lie in the same plane or to be formed by identical determinants as suggested in the figure.

(a) Complexes in extreme antibody excess. Antigen valencies saturated and molar ratio  $Ab:Ag$  approximates to the valency of the antigen.

(b) Complexes in antigen excess. In extreme excess where the two valencies of each antibody molecule become rapidly saturated, the complex  $Ag_2Ab$  tends to predominate.

(c) Large three-dimensional lattice obtained in typical immune precipitate.

(d) Monovalent antigen binds but is unable to cross-link antibody molecules.

more and more antigen is added, an optimum is reached after which consistently less precipitate is formed. At this stage the supernatant can be shown to contain soluble complexes of antigen (Ag) and antibody (Ab), many of composition  $Ag_4Ab_3$ ,  $Ag_3Ab_2$  and  $Ag_2Ab$ . In extreme antigen excess ( $AgXS$ , figure 1.3) ultracentrifugal analysis reveals the complexes to be mainly of the form  $Ag_2Ab$ , suggesting that the rabbit antibodies studied are bivalent (figure 1.4; see also figures 2.6 and 2.7). Between these extremes the crosslinking of antigen and antibody will



generally give rise to three-dimensional lattice structures, as suggested by Marrack, which coalesce to form large precipitating aggregates.

### The basis of specificity

Much of our understanding of the factors governing antigen specificity has come from the studies of Landsteiner and of Pauling and their colleagues on the interaction of antibody with small chemically defined groupings termed *haptens*, a typical example being *m*-aminobenzene sulphonate (figure 1.5). Whereas an antigen will both evoke antibody formation and combine with the resulting antibody, a *hapten* is defined as a small molecule which by itself cannot stimulate antibody synthesis but will combine with antibody once formed.

The problem of how to produce these antibodies was solved by coupling the haptens to proteins which acted as 'carriers'. It then became possible to relate variations in the chemical structure of a hapten to its ability to bind to a given antibody. In one experiment, antibodies raised to *m*-aminobenzene sulphonate were tested for their ability to combine with *ortho*, *meta* and *para* isomers of the hapten and related molecules in which the sulphonate group was substituted by arsonate or carboxylate (figure 1.6). The results are summarized in table 1.1. The hapten with the sulphonate group in the *ortho* position combines somewhat less well with the antibody than the original *meta* isomer, but the *para*-substituted compound (chemically similar to the *ortho*) shows very poor reactivity. The substitution of arsonate for sulphonate leads to weaker combination with the antibody; both groups are negatively charged and have







FIGURE 1.5. Coupling of hapten to protein by diazotization.

TABLE 1.1. Effect of variations in hapten structure on strength of binding to *m*-aminobenzene sulphonate antibodies

			
	<i>ortho</i>	<i>meta</i>	<i>para</i> isomers
R = sulphonate	++	+++	±
R = arsonate	-	+	-
R = carboxylate	-	±	-

Strength of binding is directly graded from negative (-) to very strong (+++). Since free haptens can only combine with one antibody-combining site and cannot therefore cross-link, they form only soluble complexes; their binding strength was assessed through their ability to inhibit precipitation by antibody of a new carrier protein substituted with several of the original hapten (*m*-aminobenzene sulphonate) groups per molecule (from Landsteiner K. & van der Scheer J. *J.exp.Med.* 1936, 63, 325)

a tetrahedral structure but the arsonate group is larger in size and has an extra H atom (figure 1.6). The aminobenzoates in which the sulphonate is substituted by the negatively charged but planar carboxylate group show even less affinity for the antibody. It would appear that the overall *configuration* of the hapten is even more important than its *chemical* nature, i.e. the hapten is recognized by the overall three-dimensional shape of its outer electron cloud as distinct from its chemical reactivity. The production of antibodies against such strange moieties as benzene sulphonate and arsonate becomes more comprehensible if they are thought to be directed against a particular electron-cloud shape rather than a specific chemical structure. This view is consistent with the nature of antigen-antibody binding which is known not to involve covalent linkages.




FIGURE 1.6. Configurations of the sulphonate, arsonate and carboxylate groups.

## THE FORCES BINDING ANTIGEN TO ANTIBODY

It should be stressed immediately that the forces which hold antigen and antibody together are in essence no different from the so-called 'non-specific' protein-protein interactions which occur between any two unrelated proteins (or other macromolecules) as, for example, human serum albumin and human transferrin. These intermolecular forces may be classified under four headings:

### (a) *Electrostatic*

These are due to the attraction between oppositely charged ionic groups on the two protein side chains as, for example, an ionized amino group ( $\text{NH}_3^+$ ) on a lysine of one protein and an ionized carboxyl group ( $-\text{COO}^-$ ) of, say, aspartate on the other (figure 1.7a). The force of attraction ( $F$ ) is inversely proportional to the square of the distance ( $d$ ) between the charges, i.e.

$$F \propto 1/d^2$$

Thus as the charges come closer together, the attractive force increases considerably: if we halve the distance apart, we quadruple the attraction. Dipoles on antigen and antibody can also attract each other. In addition, electrostatic forces may be generated by charge transfer reactions between antibody and antigen; for example an electron-donating protein residue such as tryptophan could part with an electron to a group such as dinitrophenyl which is electron-accepting thereby creating an effective  $+1$  charge on the antibody and  $-1$  on the antigen.

### (b) *Hydrogen bonding*

The formation of the relatively weak and reversible hydrogen bridges between hydrophilic groups such as  $-\text{OH}$ ,  $-\text{NH}_2$  and  $-\text{COOH}$  depends very much upon the close approach of the two molecules carrying these groups (figure 1.7b).

### (c) *Hydrophobic*

In the same way that oil droplets in water merge to form a single large drop, so non-polar, hydrophobic groups such as the side chains of valine, leucine and phenylalanine, tend to associate in an aqueous environment. The driving force for this hydro-